<DOC>
	<DOCNO>NCT01316094</DOCNO>
	<brief_summary>This study assess effect renal function efficacy safety ASP1941 type 2 diabetic patient mild moderate renal impairment .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety ASP1941 Diabetic Patients With Renal Impairment</brief_title>
	<detailed_description>This study conduct patient type 2 diabetes mellitus mild moderate renal impairment inadequate glycemic control exercise program stable diet , one oral hypoglycemic agent . The severity reduction renal function subject classify accord glomerular filtration rate ( GFR ) estimate use Japanese GFR estimation equation . Subjects start screen period , follow single-blind placebo run-in period , randomize ASP1941 group placebo group ratio 2:1 . For randomization , subject stratify accord severity reduction renal function . In treatment period , subject receive study drug placebo 24 week double-blind condition . At 24 week , subject willing continue participation study receive study drug another 28 week open label condition . ASP1941 increase . After completion study drug administration , follow-up period provide .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>type 2 diabetes mellitus patient subject exercise program stable diet , one oral hypoglycemic agent ( alphaglucosidase inhibitor , sulfonylurea agent pioglitazone ) estimate GFR value base Japanese GFR estimation equation â‰¥ 30 mL/min/1.73 m2 &lt; 90 mL/min/1.73 m2 HbA1C value 6.5 8.5 % body mass index ( BMI ) 29.0 45.0 kg/m2 type 1 diabetes mellitus patient proliferative diabetic retinopathy subject receive insulin within 12 week study subject chronic disease require continuous use adrenocortical steroid , immunosuppressant , loop diuretic serum creatinine &gt; upper limit normal proteinuria ( albumin/creatinine ratio &gt; 300mg/g ) dysuria and/or urinary tract infection , genital infection significant renal , hepatic cardiovascular disease severe gastrointestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Renal impairment</keyword>
	<keyword>ASP1941</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>